



**Figure S1** Effects of different concentrations of DDP and YSXZ on the cell viability of RTECs. (A) The cell viability of HKC after DDP intervention. (B) The cell viability of HKC after YSXZ intervention. \*\*\*\* $P < 0.0001$ , \*\* $P < 0.01$  compared to the CON1 group. CON1 represents FBS control. DDP, cisplatin; YSXZ, Yishen Xiezhuo formula; RTEC, renal tubular epithelial cell; HKC, human renal tubular epithelial cells; FBS, fetal bovine serum.

**Table S1** The active ingredients of YSXZ

Mol ID	Symbol	Molecule name	OB (%)	DL
MOL000211	HQ1	Mairin	55.3770734	0.7761
MOL000239	HQ2	Jaranol	50.8288168	0.29148
MOL000296	HQ3	Hederagenin	36.9139058	0.75072
MOL000033	HQ4	(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R,5S)-5-propan-2-yl-octan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol	36.2284706	0.78288
MOL000354	HQ5	Isorhamnetin	49.6043771	0.306
MOL000371	HQ6	3,9-di-O-methylnissolin	53.7415267	0.47573
MOL000374	HQ7	5'-hydroxyiso-muronulatol-2',5'-di-O-glucoside	41.7176657	0.69251
MOL000378	HQ8	7-O-methylisomucronulatol	74.6861375	0.29792
MOL000379	HQ9	9,10-dimethoxypterocarpan-3-O-β-D-glucoside	36.736688	0.9243
MOL000380	HQ10	(6aR,11aR)-9,10-dimethoxy-6a,11a-dihydro-6H-benzofurano[3,2-c]chromen-3-ol	64.2554545	0.42486
MOL000387	HQ11	Bifendate	31.0978239	0.66553
MOL000392	HQ12	Formononetin	69.6738806	0.21202
MOL000398	HQ13	Isoflavanone	109.986656	0.29572
MOL000417	HQ14	Calycosin	47.7518278	0.24278
MOL000422	HQ15	Kaempferol	41.8822495	0.24066
MOL000433	HQ16	FA	68.9604362	0.7057
MOL000438	HQ17	(3R)-3-(2-hydroxy-3,4-dimethoxyphenyl)chroman-7-ol	67.6674795	0.26479
MOL000439	HQ18	Isomucronulatol-7,2'-di-O-glucosiole	49.2810554	0.62065
MOL000442	HQ19	1,7-dihydroxy-3,9-dimethoxy pterocarpene	39.0454111	0.47943
MOL000098	A1	Quercetin	46.4333481	0.27525
MOL000359	A2	Sitosterol	36.9139058	0.7512
MOL000830	ZX2	Alisol B	34.4730731	0.81706
MOL000831	ZX3	Alisol B monoacetate	35.5762362	0.80629
MOL000832	ZX4	Alisol,b,23-acetate	32.516216	0.81841
MOL000849	ZX5	16β-methoxyalisol B monoacetate	32.4272411	0.7679
MOL000853	ZX6	Alisol B	36.7603807	0.81993
MOL000854	ZX7	Alisol C	32.7001692	0.81507
MOL000856	ZX8	Alisol C monoacetate	33.0635895	0.82763
MOL002464	ZX9	1-Monolinolein	37.1766284	0.30249
MOL000862	ZX10	[(1S,3R)-1-[(2R)-3,3-dimethyloxiran-2-yl]-3-[(5R,8S,9S,10S,11S,14R)-11-hydroxy-4,4,8,10,14-pentamethyl-3-oxo-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-17-yl]butyl] acetate	35.5762362	0.80765
MOL001002	CS1	Ellagic acid	43.0645586	0.43417
MOL001918	CS2	Paeoniflorgenone	87.5931208	0.36678

Table S1 (continued)

**Table S1** (continued)

Mol ID	Symbol	Molecule name	OB (%)	DL
MOL001921	CS3	Lactiflorin	49.1213167	0.79711
MOL001924	CS4	Paeoniflorin	53.8703752	0.78709
MOL001925	CS5	Paeoniflorin_qt	68.1757619	0.39507
MOL002714	CS6	Baicalein	33.5189187	0.20888
MOL002776	CS7	Baicalin	40.12361	0.75264
MOL000358	CS8	Beta-sitosterol	36.9139058	0.75123
MOL004355	CS10	Spinasterol	42.9793655	0.75534
MOL000449	CS11	Stigmasterol	43.8298516	0.75665
MOL000492	CS12	(+)-catechin	54.8264341	0.24164
MOL006990	CS13	(1S,2S,4R)-trans-2-hydroxy-1,8-cineole-B-D-glucopyranoside	30.2524116	0.27464
MOL006992	CS14	(2R,3R)-4-methoxyl-distylin	59.983251	0.29949
MOL006994	CS15	1-o-beta-d-glucopyranosyl-8-o-benzoylpaeonisuffrone_qt	36.013058	0.29897
MOL006996	CS16	1-o-beta-d-glucopyranosylpaeonisuffrone_qt	65.0818665	0.35391
MOL006999	CS17	Stigmast-7-en-3-ol	37.4231207	0.75088
MOL007003	CS18	Benzoyl paeoniflorin	31.1386658	0.54227
MOL007004	CS19	Albiflorin	30.2461429	0.77038
MOL007005	CS20	Albiflorin_qt	48.7001165	0.32628
MOL007008	CS21	4-ethyl-paeoniflorin_qt	56.8695773	0.44483
MOL007012	CS22	4-o-methyl-paeoniflorin_qt	56.7035174	0.42562
MOL007014	CS23	8-debenzoylpaeonidanin	31.7431484	0.45389
MOL007016	CS24	Paeoniflorigenone	65.3341131	0.36711
MOL007018	CS25	9-ethyl-neo-paeoniaflorin A_qt	64.4198931	0.29598
MOL007022	CS26	EvofofinB	64.736617	0.22232
MOL007025	CS27	Isobenzoylpaeoniflorin	31.1386658	0.54234
MOL002883	CS28	Ethyl oleate (NF)	32.3973882	0.19061
MOL005043	CS29	Campest-5-en-3beta-ol	37.5768179	0.71481
MOL010578	HZ1	N-[(1S)-1-(benzyl)-2-[[[(1S)-1-(benzyl)-2-hydroxy-ethyl]amino]-2-keto-ethyl]benzamide	45.7583125	0.43303
MOL010580	HZ2	Diglycol dibenzoate	59.2188542	0.27376
MOL005440	HZ3	Isofucosterol	43.7763956	0.7576

The data was provided by TCMSP (<https://old.tcmsp-e.com/tcmsp.php>). YSXZ, Yishen Xiezhuo formula; OB, oral bioavailability; DL, drug-like properties; TCMSP, Traditional Chinese Medicine Systems Pharmacology.

**Table S2** The common targets name of YSXZ and AKI

<i>PGR</i>	<i>PDE3A</i>	<i>ADRA1D</i>	<i>TNF</i>	<i>MMP3</i>	<i>ERBB2</i>	<i>NQO1</i>	<i>NPEPPS</i>
<i>NOS2</i>	<i>SLC6A2</i>	<i>OPRM1</i>	<i>AHSA1</i>	<i>EGFR</i>	<i>ACACA</i>	<i>TNKS</i>	<i>HK2</i>
<i>PTGS1</i>	<i>ESR1</i>	<i>DRD1</i>	<i>CASP3</i>	<i>CCND1</i>	<i>CAV1</i>	<i>COL3A1</i>	<i>NKX3-1</i>
<i>AR</i>	<i>PPARG</i>	<i>KCNH2</i>	<i>MAPK8</i>	<i>BCL2L1</i>	<i>MYC</i>	<i>CXCL11</i>	<i>RASA1</i>
<i>SCN5A</i>	<i>PTPN1</i>	<i>F10</i>	<i>MMP1</i>	<i>FOS</i>	<i>F3</i>	<i>CXCL2</i>	<i>NR3C2</i>
<i>PTGS2</i>	<i>MAPK14</i>	<i>OPRD1</i>	<i>STAT1</i>	<i>CDKN1A</i>	<i>GJA1</i>	<i>DCAF5</i>	<i>NR3C1</i>
<i>ESR2</i>	<i>GSK3B</i>	<i>HTR2A</i>	<i>HMOX1</i>	<i>EIF6</i>	<i>IL1B</i>	<i>CHEK2</i>	<i>GSTA2</i>
<i>DPP4</i>	<i>PIK3CG</i>	<i>ADRA1A</i>	<i>CYP3A4</i>	<i>CASP9</i>	<i>CCL2</i>	<i>CLDN4</i>	<i>CD14</i>
<i>HSP90AA1</i>	<i>PRKACA</i>	<i>SLC6A3</i>	<i>CYP1A1</i>	<i>PLAU</i>	<i>PTGER3</i>	<i>PPARA</i>	<i>LBP</i>
<i>CDK2</i>	<i>PIM1</i>	<i>SLC6A4</i>	<i>ICAM1</i>	<i>MMP2</i>	<i>CXCL8</i>	<i>HSF1</i>	<i>FOSL1</i>
<i>CHEK1</i>	<i>CCNA2</i>	<i>KCNMA1</i>	<i>SELE</i>	<i>MMP9</i>	<i>PRKCB</i>	<i>CRP</i>	<i>FOSL2</i>
<i>PRSS1</i>	<i>PYGM</i>	<i>TOP2A</i>	<i>VCAM1</i>	<i>MAPK1</i>	<i>BIRC5</i>	<i>CXCL10</i>	<i>CYCS</i>
<i>NCOA2</i>	<i>PPARD</i>	<i>CHRNA7</i>	<i>NR1I2</i>	<i>IL10</i>	<i>DUOX2</i>	<i>CHUK</i>	<i>ALOX12</i>
<i>CALM</i>	<i>AKR1B1</i>	<i>KDR</i>	<i>CYP1B1</i>	<i>RB1</i>	<i>HSPB1</i>	<i>SPP1</i>	<i>NFATC1</i>
<i>CHRM3</i>	<i>NCOA1</i>	<i>MET</i>	<i>ALOX5</i>	<i>IL6</i>	<i>TGFB1</i>	<i>RUNX2</i>	<i>EGLN1</i>
<i>CHRM1</i>	<i>F7</i>	<i>DPEP1</i>	<i>HAS2</i>	<i>TP53</i>	<i>MGAM</i>	<i>RASSF1</i>	<i>NOX5</i>
<i>GABRA2</i>	<i>F2</i>	<i>JUN</i>	<i>AHR</i>	<i>ELK1</i>	<i>IL2</i>	<i>E2F1</i>	<i>FABP5</i>
<i>GABRA3</i>	<i>NOS3</i>	<i>IL4</i>	<i>PSMD3</i>	<i>NFKBIA</i>	<i>CCNB1</i>	<i>E2F2</i>	<i>APOD</i>
<i>CHRM2</i>	<i>ACHE</i>	<i>SIRT1</i>	<i>SLC2A4</i>	<i>ODC1</i>	<i>PLAT</i>	<i>ACP3</i>	<i>CHRNA2</i>
<i>ADRA1B</i>	<i>MAOB</i>	<i>ATP5F1B</i>	<i>NR1I3</i>	<i>CASP8</i>	<i>THBD</i>	<i>CTSD</i>	<i>MAP2</i>
<i>GABRA1</i>	<i>RELA</i>	<i>MT-ND6</i>	<i>INSR</i>	<i>TOP1</i>	<i>SERPINE1</i>	<i>IGFBP3</i>	<i>ADRA2A</i>
<i>GRIA2</i>	<i>XDH</i>	<i>HSD3B2</i>	<i>DIO1</i>	<i>RAF1</i>	<i>IFNG</i>	<i>IGF2</i>	<i>LTA4H</i>
<i>GABRA6</i>	<i>NCF1</i>	<i>HSD3B1</i>	<i>PPP3CA</i>	<i>SOD1</i>	<i>PTEN</i>	<i>CD40LG</i>	<i>MAOA</i>
<i>GABRA5</i>	<i>OLR1</i>	<i>IKBKB</i>	<i>GSTM1</i>	<i>PRKCA</i>	<i>IL1A</i>	<i>IRF1</i>	<i>CTRB1</i>
<i>IGHG1</i>	<i>ADRB1</i>	<i>AKT1</i>	<i>GSTM2</i>	<i>HIF1A</i>	<i>MPO</i>	<i>ERBB3</i>	<i>ABAT</i>
<i>LYZ</i>	<i>ADRA2C</i>	<i>BCL2</i>	<i>AKR1C3</i>	<i>RUNX1T1</i>	<i>ABCG2</i>	<i>PON1</i>	
<i>RXRA</i>	<i>ADRB2</i>	<i>BAX</i>	<i>SLPI</i>	<i>HSPA5</i>	<i>NFE2L2</i>	<i>PCOLCE</i>	

YSXZ, Yishen Xiezhuo formula; AKI, acute kidney injury.